SRR1336292
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.444
- KRAS_SIGNALING_DN+0.439
- APICAL_SURFACE+0.365
- COAGULATION+0.322
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.307
- MYOGENESIS+0.280
- HEDGEHOG_SIGNALING+0.249
- ESTROGEN_RESPONSE_EARLY+0.248
- ESTROGEN_RESPONSE_LATE+0.248
- ANGIOGENESIS+0.246
Top 10 suppressed
- MYC_TARGETS_V1-0.674
- OXIDATIVE_PHOSPHORYLATION-0.592
- MYC_TARGETS_V2-0.570
- DNA_REPAIR-0.553
- E2F_TARGETS-0.498
- PROTEIN_SECRETION-0.482
- UNFOLDED_PROTEIN_RESPONSE-0.478
- G2M_CHECKPOINT-0.420
- MTORC1_SIGNALING-0.398
- ADIPOGENESIS-0.359
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR612563 | GTEX | — | 0.952 |
| 2 | SRR1360104 | GTEX | — | 0.948 |
| 3 | SRR1330061 | GTEX | — | 0.943 |
| 4 | SRR1444479 | GTEX | — | 0.940 |
| 5 | SRR1339651 | GTEX | — | 0.935 |
| 6 | MNG298 | — | — | 0.933 |
| 7 | MNG204 | — | — | 0.933 |
| 8 | SRR1353221 | GTEX | — | 0.933 |
| 9 | BS_27QE6BV7 | Ganglioglioma | — | 0.928 |
| 10 | SRR602839 | GTEX | — | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.444 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.439 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.365 | Temsirolimus | — uncovered |
| COAGULATION | 0.322 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.307 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.249 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.248 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.248 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.246 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.218 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.172 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.168 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.165 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.158 | Inavolisib | — uncovered |
| COMPLEMENT | 0.156 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.139 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.129 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.105 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.089 | Idelalisib | — uncovered |